Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials.

doi:10.1016/j.ejca.2013.02.007

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials.

European journal of cancer (Oxford, England : 1990) - 1 Jun 2013

Okines A F C, Gonzalez de Castro D, Cunningham D, Chau I, Langley R E, Thompson L C, Stenning S P, Saffery C, Barbachano Y, Coxon F, Middleton G, Ferry D, Crosby T, Madhusudan S, Wadsley J, Waters J, Hall M, Swinson D, Robinson A, Smith D, Reis-Filho J S, Waddell T S, Puckey L, Hulkki Wilson S, Eltahir Z, Band M, Wotherspoon A

Abstract excerpt

BACKGROUND: REAL3 (Randomised ECF for Advanced or Locally advanced oesophagogastric cancer 3) was a phase II/III trial designed to evaluate the addition of panitumumab (P) to epirubicin, oxaliplatin and capecitabine (EOC) in untreated advanced oesophagogastric adenocarcinoma, or undifferentiated carcinoma. MAGIC (MRC Adjuvant Gastric Infusional Chemotherapy) was a phase III study which demonstrated that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Esophageal Neoplasms

Share to Phosphatidylinositol 3-Kinases

Share to PTEN Phosphohydrolase

Share to ras Proteins

Share to Stomach Neoplasms

Share to Survival Analysis

Source

Open in PubMed

Identifiers

PMID: 23481512
DOI: 10.1016/j.ejca.2013.02.007

Genes

BRAF
KRAS
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials.PMID 23481512Read ↗

Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801).Semantic proximity Read ↗

A systematic approach to therapeutic target selection in oesophago-gastric cancerSemantic proximity Read ↗

EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.Semantic proximity Read ↗

PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.Semantic proximity Read ↗

The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancerSemantic proximity Read ↗

Efficacy and safety of neoadjuvant toripalimab plus chemotherapy in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma (NICE): a multicentre, single-arm, exploratory phase 2 studySemantic proximity Read ↗

Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.Semantic proximity Read ↗

Evaluating Many Treatments and Biomarkers in Oncology: A New DesignSemantic proximity Read ↗

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.Semantic proximity Read ↗

A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer.Semantic proximity Read ↗

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.Semantic proximity Read ↗

New directions in perioperative management of locally advanced esophagogastric cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.